ITCMDBv1
Clinical TrialID 7412

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

NCT05481658

Cutaneous Metastases

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
7412
Evidence Id
7412
Core Evidence Id
7412
Source Clinical Trial Id
7407
Herb2 Clinical Trial Id
HBCT007407
Nct Id
NCT05481658
Title
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Status
Recruiting
Phase
Phase 1
Study Result
No
Study Condition
Cutaneous Metastases
Study Type
Interventional
Study Design
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: Diphencyprone (DPCP)
Intervention Allocation
Intervention Model
Single_Group
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
27
Outcome Measure
Proportion of subjects with a grade 3 adverse event, Safety and tolerability of dual-therapy DPCP plus immune checkpoint inhibition will be measured as the proportion of subjects with a grade 3 on the Common Terminology Criteria for Adverse Events (CTCAE) criteria for eczema, version 5.0., at Day 98 or 128
Sponsor Collaborator
Nicholas Gulati
Funded By
OTHER
Location
Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States
Other Id
STUDY-21-01421
Start Date
2022-10-06
Primary Completion Date
2024-12
Completion Date
2024-12
First Posted
2022-08-01
Results First Posted
Last Update Posted
2024-09-24
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05481658
Title Cn
Title En
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Bilingual Status
semi_complete